Trials / Terminated
TerminatedNCT04547101
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
A Single-arm, Open-label, Multicenter, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | AK104，6 mg/kg IV，every 2 weeks (Q2W) |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2020-09-14
- Last updated
- 2022-10-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04547101. Inclusion in this directory is not an endorsement.